Pharmacokinetic data from a randomized, parallel-group, multicenter study are presented. Adults with toenail onychomycosis (n ‫؍‬ 146) received posaconazole (100 mg, 200 mg, or 400 mg) once daily (QD) for 24 weeks or 400 mg QD for 12 weeks. The posaconazole concentration in the great toenail exhibited a dose-related increase starting at week 2 for 24 weeks and a mean toenail-to-plasma concentration ratio of approximately 3:1 at the end of treatment for the 400-mg 24-week dose.
Posaconazole, a triazole antifungal, has potent in vitro activity against dermatophyte pathogens of onychomycosis (3) . Pharmacokinetic (PK) data exist for the distribution of posaconazole within the skin (4), but no PK data exist for posaconazole distribution in toenails. This article presents PK data from a phase 2 clinical trial of posaconazole in the treatment of onychomycosis (ClinicalTrials.gov identifier NCT00491764).
(Parts of this work were presented at the 68th Annual Meeting of the American Academy of Dermatology, Miami Beach, FL, 5 to 9 March 2010).
This was a randomized, placebo-and active-controlled, parallel-group, multicenter, investigator-blinded study. After a 12-or 24-week treatment period, all patients were followed until 48 weeks after their first dose (i.e., a 24-or 36-week follow-up period). Patients received posaconazole at 100 mg, 200 mg, or 400 mg once daily (QD) for 24 weeks or 400 mg QD for 12 weeks, terbinafine (250 mg QD for 12 weeks), or a placebo (matched to posaconazole) for 24 weeks. Only patients receiving posaconazole were included in this PK analysis.
The study protocol was approved by an appropriate ethics committee or institutional review board at each center and was carried out in accordance with good clinical practices. Written informed consent was obtained from each patient before enrollment. Patients were ages 18 to 75 years, had a clinical and mycologic diagnosis of onychomycosis affecting ϳ25% to 75% of at least 1 great toenail, and were otherwise in good health. Patients receiving systemic antifungal therapy within 3 months of study entry or topical foot or toenail antifungal therapy within 1 month of study entry were excluded, as were patients taking drugs known to interact with or be metabolized by cytochrome P450 3A4 within 2 weeks of randomization. Patients could not be pregnant or breastfeeding.
Predose blood and toenail samples were collected from all 10 toes at each visit (day 1 and weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48). Toenail clippings (without subungual debris) were obtained and stored frozen at Ϫ20°C until they were shipped to Covance Laboratories Inc., Madison, WI, for assay. A validated standard curve was constructed with untreated human nails from healthy volunteers as the matrix. Toenail samples were mixed with 1.00 ml of 1 M sodium hydroxide per 10.0 mg of toenail, placed in a shaking water bath at 70°C for at least 1 h, and then vortexed for ϳ30 s. Hydrolyzed toenail solution (1.00 ml) was mixed with methanol-water (50:50 [vol/vol]; 0.05 ml) and ethyl acetate-dichloromethane (75:25 [vol/vol]; 5.00 ml), placed on a horizontal shaker for 10 min at ϳ120 cycles/min, and then centrifuged at 2,500 rpm for 5 min at room temperature. The aqueous layer was frozen in a dry ice-acetone bath, and the organic layer was collected and evaporated under nitrogen in a TurboVap concentration workstation (Caliper Life Sciences, Hopkinton, MA) at 40°C for ϳ20 min. Samples were reconstituted for analysis with 0.40 ml 0.1% formic acid in acetonitrile-water (50:50 [vol/vol] ) and vortexed at high speed.
Plasma and toenail samples were assayed for posaconazole using validated liquid chromatography with tandem mass spectrometric detection as previously published (6). The lower limit of quantitation for posaconazole was 5.00 ng/ml, the calibration range was 5.00 to 5,000 ng/ml, precision (coefficient of variation [CV%]) was 4.4 to 6.7, and accuracy was Ϫ3.0% to 0.0%.
Plasma and toenail concentration data were used to estimate the maximum observed posaconazole concentration (C max ), minimum observed posaconazole concentration (C min ), and time to C max (T max ). Plasma and toenail posaconazole concentrations and the derived PK parameters were listed and summarized using descriptive statistics.
Safety parameters included monitoring of adverse events (AEs), electrocardiogram, monitoring of vital signs, physical examinations, and laboratory safety tests.
A total of 146/218 randomized patients received one of the posaconazole doses; 118 of them completed treatment. Demographic characteristics are shown in Table 1 and appear similar between the treatment groups.
The PK results include all patients treated with posaconazole who had baseline (i.e., pretreatment) PK data and at least 1 posttreatment PK assessment available. Posaconazole PK parameters in plasma and toenails following multiple oral doses of posaconazole QD for 12 and 24 weeks are presented in Table 2 . Mean posaconazole plasma concentrations showed a dose-related increase and were characterized by virtually flat plasma concentration-time profiles once steady state was attained (Fig. 1A) . In the great toenail, posaconazole was detected as early as 2 weeks for the 200-and 400-mg dose groups. In general, the concentration of posaconazole in the great toenail exhibited a dose-related increase (100 to 400 mg QD for 24 weeks), and levels continued to increase even after discontinuation of treatment (Fig. 1B) , whereas plasma levels, as expected, declined shortly after discontinuation of treatment (Fig. 1A) . The T max of posaconazole in the great toenail was achieved in 36 to 42 weeks. The great-toenail-to-plasma mean concentration ratio ranged from 1.3 to 2.9 at the end of treatment (24 weeks) ( Table 2 ). The CV% of posaconazole exposure in toenails was higher than that in plasma (51% to 137% for the toenail C max versus 50% to 76% for the plasma C min ). Posaconazole diffusion into the nail plate, presumably via the nail plate bed, is likely to be consistent with that observed for other systemically administered antifungals, such as terbinafine, itraconazole, and fluconazole (1, 2, 5) . Levels of posaconazole in the nail remained high after treatment was discontinued, probably because posaconazole accumulated in the nail matrix via systemic absorption during treatment. As the nail plate grew out, posaconazole was incorporated into the nail plate, moving away from the nail fold, where it persisted at the distal end of the nail plate. It would be expected that at earlier time points, drug diffusion across the nail bed into the nail plate would also contribute to posaconazole levels in the nail. The structurally similar itraconazole has also been reported to reach the nail by diffusion across the nail bed and by incorporation into the matrix (7).
There were no major safety concerns with any of the safety parameters. There were four serious AEs; none was considered treatment related.
These findings demonstrate penetration into the nail by posaconazole that may have implications for treatment of mycotic nail infections. Further clinical studies may be needed to com- 
